I really cannot trust Cempra's analysis one way or the other. According to Japan's public clinicaltrials site, there are three soli trials, but Cempra keeps saying one CABP and doesn't mention the others. And how many patients will it enroll? No one (at least investors) know. Half of those patients can be added to the safety study. Maybe even you could add patients from the non-CABP studies because after all the FDA did count people from different studies to the current overall database.
Let's say there are in total 1.2K patients being treated in all 3 studies. So that reduces the sum by 20%. Assuming you trust the 75m figure, then that is 60m. And BARDA already committed more than this on the pediatric program -- $68.2m. I don't know if they'll foot the bill 100%, but maybe half-way. Then get Menarini to pay the other half for a contract. They are already paying for half of the CABP Baxdela trial, which maybe costs something like $20-$25m.
It's totally do-able.
About the salespeople: https://www.sec.gov/Archives/edgar/data/1461993/000119312517281202/g438060ex99_1s11g1.jpg -- sales force to expand based on adoption. A smart build-out strategy.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM